Devising effective manufacturing and quality control methods for cell therapies
Regenerative therapies are proving their potential in cell-based therapies for chronic disorders. Following on from its previous three editions, this conference aims to provide an illustrative summary of recent developments in the technologies enabling the bioprocessing of cellular therapies, process development and addressing qualitative and regulatory hurdles.
In this 4th edition of MarketsandMarkets Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine, the focus will be on the manufacturing, clinical and regulatory aspects of cell therapies and regenerative medicine. Special attention will be paid to tissue engineering, car-T cell-based immunotherapies, automated manufacturing, allogeneic therapies, with the aspects of hurdles in supply chain management and regulatory affairs.
Mogrify™ has developed a proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.